Sarepta Therapeutics’ Q3 2018 Earnings: What Can We Expect?

Top-line forecast

Sarepta Therapeutics (SRPT) is expected to report its third quarter of fiscal 2018 earnings on October 24. Analysts expect revenues to increase 72.27% to $79.17 million, from $45.95 million in the third quarter of fiscal 2017.

Sarepta Therapeutics’ Q3 2018 Earnings: What Can We Expect?

For fiscal 2018 and fiscal 2019, Sarepta Therapeutics is expected to generate revenues of $302.12 million and $429.78 million, respectively. In fiscal 2017, its revenues were $154.58 million. Its gross margin is expected to contract from 93.3% in the third quarter of fiscal 2017 to 84.55% in the third quarter of fiscal 2018.

Operational performance

Sarepta Therapeutics is expected to incur selling, general, and administrative expenses of $47.7 million in the third quarter of 2018 compared to $62.41 million in the third quarter of 2017, a decrease of 23.57%.

Its research and development expenses, on the other hand, are expected to increase to $68.83 million from $34.24 million in Q3 2017.

Bottom line

Sarepta Therapeutics is expected to incur a net loss of $50.95 million in the third quarter of 2018. Its net loss was $47.73 million in the same quarter last year. That translates to a net loss per share of $0.74 compared to a net loss per share of $0.78 in the third quarter of fiscal 2017.